Skip to main content

Table 2 Primary endpoint: total number of diarrhea days (PP set)

From: A double-blind, randomized, placebo-controlled trial studying the effects of Saccharomyces boulardii on the gastrointestinal tolerability, safety, and pharmacokinetics of miglustat

Total number of diarrhea days Miglustat + S. boulardii Miglustat + placebo Paired difference P-value
(n = 34) (n = 34) (n = 34)
Mean (SD) 0.8 (2.4) 1.3 (2.4) −0.5 (2.4) 0.159*
Range (min, max) 0, 13 0, 8 −7, 8
95 % CI of mean 0, 1.67 0.46, 2.13 −1.31, 0.37
Median 0 0 0
Q1, Q3 (0, 0) (0, 1) (−1, 0)
95 % CI of median 0, 0 0, 1.00 0, 0
  1. *Based on paired t test; p = 0.042 based on Wilcoxon paired signed rank test after one outlying subject was excluded during the post-hoc sensitivity analysis